LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Joy, Tisha R"
  2. AU="Özil, Musa"
  3. AU="Franci, Lorenzo"
  4. AU="Khoobdel, Mehdi"
  5. AU="Ian B Wilkinson"
  6. AU="Sarpün, I.H."
  7. AU="Gums, Jeremiah J"
  8. AU="Petsalaki, Eleni"
  9. AU="Yu, Weichao"
  10. AU="Mertens, Anne Wiebke"
  11. AU="Roitershtein, Alexander"
  12. AU="Deppen, Stephen"
  13. AU="Goliath, Rene"
  14. AU="Emons, Günter"
  15. AU="Sarah S. Barnett"

Suchergebnis

Treffer 1 - 10 von insgesamt 25

Suchoptionen

  1. Artikel ; Online: Strategies For Enhancing Equity, Diversity, and Inclusion in Medical School Admissions-A Canadian Medical School's Journey.

    Joy, Tisha R

    Frontiers in public health

    2022  Band 10, Seite(n) 879173

    Abstract: Background: Medical schools aim to select and train future physicians representative of and able to serve their diverse population needs. Enhancing equity, diversity, and inclusion (EDI) in admissions processes includes identifying and mitigating ... ...

    Abstract Background: Medical schools aim to select and train future physicians representative of and able to serve their diverse population needs. Enhancing equity, diversity, and inclusion (EDI) in admissions processes includes identifying and mitigating barriers for those underrepresented in medicine (URM).
    Summary of innovations: In 2017, Schulich School of Medicine and Dentistry (Western University, Ontario, Canada) critically reviewed its general Admissions pathways for the Doctor of Medicine (MD) program. Till that time, interview invitations were primarily based on academic metrics rather than a holistic review as for its Indigenous MD Admissions pathway. To help diversify the Canadian physician workforce, Schulich Medicine utilized a multipronged approach with five key changes implemented over 2 years into the general MD Admissions pathways: 1. A voluntary applicant diversity survey (race, socioeconomic status, and community size) to examine potential barriers within the Admissions process; 2. Diversification of the admissions committee and evaluator pool with the inclusion of an Equity Representative on the admissions committee; 3. A biosketch for applicants' life experiences; 4. Implicit bias awareness training for Committee members, file reviewers and interviewers; and 5. A specific pathway for applicants with financial, sociocultural, and medical barriers (termed ACCESS pathway). Diversity data before (Class of 2022) vs. after (Class of 2024) these initiatives and of the applicant pool vs. admitted class were examined.
    Conclusion: For the Class of 2024, the percentage of admitted racialized students (55.2%), those with socioeconomic challenges (32.3%), and those from remote/rural/small town communities (18.6%) reflected applicant pool demographics (52.8, 29.9, and 17.2%, respectively). Additionally, 5.3% (vs. 5.6% applicant pool) of admitted students had applied through ACCESS. These data suggest that barriers within the admissions process for these URM populations were potentially mitigated by these initiatives. The initiatives broadly improved representation of racialized students, LGBTQ2S+, and those with disability with statistically significant increases in representation of those with socioeconomic challenges (32.3 vs. 19.3%,
    Mesh-Begriff(e) Canada ; Humans ; Minority Groups ; School Admission Criteria ; Schools, Medical ; Social Class
    Sprache Englisch
    Erscheinungsdatum 2022-06-24
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2711781-9
    ISSN 2296-2565 ; 2296-2565
    ISSN (online) 2296-2565
    ISSN 2296-2565
    DOI 10.3389/fpubh.2022.879173
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Management Strategies for Statin-Associated Muscle Symptoms: How Useful Is Same-Statin Rechallenge?

    Brennan, Emily T / Joy, Tisha R

    The Canadian journal of cardiology

    2017  Band 33, Heft 5, Seite(n) 666–673

    Abstract: Background: Statin-associated muscle symptoms (SAMS) are common. Rechallenge with the same statin (same-statin rechallenge) has recently been included as part of a proposed scoring index for diagnosing SAMS, but data regarding tolerability and efficacy ... ...

    Abstract Background: Statin-associated muscle symptoms (SAMS) are common. Rechallenge with the same statin (same-statin rechallenge) has recently been included as part of a proposed scoring index for diagnosing SAMS, but data regarding tolerability and efficacy of same-statin rechallenge, compared with other strategies, is minimal. In this study we evaluated the tolerability, percent change in low-density lipoprotein cholesterol (LDL-C), and proportion of patients achieving their LDL-C targets among 3 common management strategies-same-statin rechallenge, switching to a different statin (statin switch), and use of nonstatin medications only.
    Methods: We performed a retrospective analysis of 118 patients referred to our tertiary care centre for management of SAMS, defined as development of muscle-related symptoms with 2 or more statins. Baseline and last follow-up lipid parameters were documented. Patients were classified as tolerant of a strategy if, at their last follow-up, they remained on that strategy.
    Results: After a median follow-up of 17 months, most (n = 79; 67%) patients were able to tolerate a statin. Tolerability was similar among the 3 treatment strategies (71% same-statin rechallenge vs 53% statin switch vs 57% for nonstatin therapy only; P = 0.11). Those in the same-statin rechallenge and statin switch groups achieved greater LDL-C reductions compared with those who only tolerated nonstatins (-38.8 ± 3.4% vs -36.4 ± 2.9% vs -17.3 ± 4.5%; P = 0.0007). A greater proportion of patients in the same-statin rechallenge group achieved their target LDL-C compared with those in the nonstatin therapy only group (50% vs 15%; odds ratio, 6.8; 95% confidence interval, 1.5-40.7; P = 0.04).
    Conclusions: Among individuals with a history of SAMS, most will tolerate statin therapy. Same-statin rechallenge was highly tolerable and efficacious. Thus, same-statin rechallenge might warrant increased utilization.
    Mesh-Begriff(e) Aged ; Canada/ethnology ; Cholesterol, LDL/analysis ; Cholesterol, LDL/metabolism ; Drug Substitution/methods ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Hypercholesterolemia/drug therapy ; Hypercholesterolemia/epidemiology ; Hypercholesterolemia/metabolism ; Lipid Metabolism/drug effects ; Male ; Medication Therapy Management ; Middle Aged ; Muscular Diseases/chemically induced ; Muscular Diseases/diagnosis ; Muscular Diseases/epidemiology ; Muscular Diseases/prevention & control ; No-Observed-Adverse-Effect Level ; Retrospective Studies ; Treatment Outcome
    Chemische Substanzen Cholesterol, LDL ; Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Sprache Englisch
    Erscheinungsdatum 2017-05
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 632813-1
    ISSN 1916-7075 ; 0828-282X
    ISSN (online) 1916-7075
    ISSN 0828-282X
    DOI 10.1016/j.cjca.2017.02.013
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Novel HDL-based therapeutic agents.

    Joy, Tisha R

    Pharmacology & therapeutics

    2012  Band 135, Heft 1, Seite(n) 18–30

    Abstract: Reduction in low-density lipoprotein cholesterol (LDL-C) levels has been associated with a 25-30% reduction in cardiovascular disease risk. However, there still remains a significant and quantifiable risk. Since epidemiologic data have demonstrated that ... ...

    Abstract Reduction in low-density lipoprotein cholesterol (LDL-C) levels has been associated with a 25-30% reduction in cardiovascular disease risk. However, there still remains a significant and quantifiable risk. Since epidemiologic data have demonstrated that low levels of high-density lipoprotein cholesterol (HDL-C) are associated with an increased risk for cardiovascular disease, novel therapeutic agents are currently being developed to either raise HDL-C levels or enhance HDL functionality. This review will highlight some of these therapeutic agents including cholesteryl ester transfer protein inhibitors, apolipoprotein A-I mimetics, RVX-208, and apolipoprotein A-I based infusion therapies. For each therapeutic class, an overview of the mechanism of action, pharmacokinetic data, and efficacy/safety evidence will be provided.
    Mesh-Begriff(e) Animals ; Apolipoprotein A-I/therapeutic use ; Biomarkers/blood ; Cardiovascular Diseases/blood ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/prevention & control ; Cholesterol Ester Transfer Proteins/antagonists & inhibitors ; Cholesterol Ester Transfer Proteins/blood ; Cholesterol, HDL/blood ; Cholesterol, LDL/blood ; Dyslipidemias/blood ; Dyslipidemias/complications ; Dyslipidemias/drug therapy ; Humans ; Hypolipidemic Agents/adverse effects ; Hypolipidemic Agents/pharmacokinetics ; Hypolipidemic Agents/therapeutic use ; Molecular Mimicry ; Quinazolines/therapeutic use ; Treatment Outcome
    Chemische Substanzen Apolipoprotein A-I ; Biomarkers ; CETP protein, human ; Cholesterol Ester Transfer Proteins ; Cholesterol, HDL ; Cholesterol, LDL ; Hypolipidemic Agents ; Quinazolines ; apabetalone (8R4A7GDZ1D)
    Sprache Englisch
    Erscheinungsdatum 2012-03-23
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 194735-7
    ISSN 1879-016X ; 0163-7258
    ISSN (online) 1879-016X
    ISSN 0163-7258
    DOI 10.1016/j.pharmthera.2012.03.004
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Novel therapeutic agents for lowering low density lipoprotein cholesterol.

    Joy, Tisha R

    Pharmacology & therapeutics

    2012  Band 135, Heft 1, Seite(n) 31–43

    Abstract: Elevated low density lipoprotein cholesterol (LDL-C) levels have been associated with an increased risk for cardiovascular disease (CVD). Despite a 25-30% reduction in CVD risk with LDL-C reducing strategies, there is still a significant residual risk. ... ...

    Abstract Elevated low density lipoprotein cholesterol (LDL-C) levels have been associated with an increased risk for cardiovascular disease (CVD). Despite a 25-30% reduction in CVD risk with LDL-C reducing strategies, there is still a significant residual risk. Moreover, achieving target LDL-C values in individuals at high CVD risk is sometimes limited because of tolerability and/or efficacy. Thus, novel therapeutic agents are currently being developed to lower LDL-C levels further. This review will highlight some of these therapeutic agents including anti-sense oligonucleotides focused on apolipoprotein B, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, microsomal triglyceride transfer protein inhibitors, and thyromimetics. For each therapeutic class, an overview of the mechanism of action, pharmacokinetic data, and efficacy/safety evidence will be provided.
    Mesh-Begriff(e) Animals ; Anticholesteremic Agents/adverse effects ; Anticholesteremic Agents/pharmacokinetics ; Anticholesteremic Agents/therapeutic use ; Apolipoproteins B/blood ; Apolipoproteins B/genetics ; Biomarkers/blood ; Biomimetic Materials/therapeutic use ; Cardiovascular Diseases/blood ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/genetics ; Cardiovascular Diseases/prevention & control ; Carrier Proteins/antagonists & inhibitors ; Carrier Proteins/metabolism ; Cholesterol, LDL/blood ; Down-Regulation ; Humans ; Hypercholesterolemia/blood ; Hypercholesterolemia/complications ; Hypercholesterolemia/drug therapy ; Hypercholesterolemia/genetics ; Oligonucleotides, Antisense/therapeutic use ; Proprotein Convertase 9 ; Proprotein Convertases/antagonists & inhibitors ; Proprotein Convertases/metabolism ; Protein Kinase Inhibitors/therapeutic use ; Serine Endopeptidases/metabolism ; Thyroid Hormones/metabolism ; Treatment Outcome
    Chemische Substanzen Anticholesteremic Agents ; Apolipoproteins B ; Biomarkers ; Carrier Proteins ; Cholesterol, LDL ; Oligonucleotides, Antisense ; Protein Kinase Inhibitors ; Thyroid Hormones ; microsomal triglyceride transfer protein ; PCSK9 protein, human (EC 3.4.21.-) ; Proprotein Convertase 9 (EC 3.4.21.-) ; Proprotein Convertases (EC 3.4.21.-) ; Serine Endopeptidases (EC 3.4.21.-)
    Sprache Englisch
    Erscheinungsdatum 2012-07
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 194735-7
    ISSN 1879-016X ; 0163-7258
    ISSN (online) 1879-016X
    ISSN 0163-7258
    DOI 10.1016/j.pharmthera.2012.03.005
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel: Management strategies in patients with statin-associated muscle symptoms: What is the best strategy?

    Joy, Tisha R / Brennan, Emily T

    Journal of clinical lipidology

    2016  Band 10, Heft 5, Seite(n) 1067–1072

    Mesh-Begriff(e) Dose-Response Relationship, Drug ; Drug Substitution/methods ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Lipid Metabolism/drug effects ; Medication Therapy Management ; Muscular Diseases/etiology ; Muscular Diseases/prevention & control
    Chemische Substanzen Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Sprache Englisch
    Erscheinungsdatum 2016-06-25
    Erscheinungsland United States
    Dokumenttyp Editorial
    ZDB-ID 2365061-8
    ISSN 1876-4789 ; 1933-2874
    ISSN (online) 1876-4789
    ISSN 1933-2874
    DOI 10.1016/j.jacl.2016.06.008
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Bilateral adrenal histoplasmosis manifesting as primary adrenal insufficiency.

    Robinson, Lilian J / Lu, Mary / Elsayed, Sameer / Joy, Tisha R

    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

    2019  Band 191, Heft 44, Seite(n) E1217–E1221

    Mesh-Begriff(e) Adrenal Glands/diagnostic imaging ; Adrenal Glands/pathology ; Adrenal Insufficiency/diagnostic imaging ; Adrenal Insufficiency/drug therapy ; Adrenal Insufficiency/microbiology ; Adrenal Insufficiency/pathology ; Aged ; Antifungal Agents/therapeutic use ; Diagnosis, Differential ; Fatigue/microbiology ; Female ; Glucocorticoids/therapeutic use ; Histoplasmosis/diagnostic imaging ; Histoplasmosis/drug therapy ; Histoplasmosis/pathology ; Humans ; Hyperpigmentation/microbiology ; Hyperpigmentation/pathology ; Mineralocorticoids/therapeutic use ; Muscle Weakness/diagnostic imaging ; Muscle Weakness/microbiology ; Muscle Weakness/pathology ; Tomography, X-Ray Computed ; Treatment Outcome ; Weight Loss
    Chemische Substanzen Antifungal Agents ; Glucocorticoids ; Mineralocorticoids
    Sprache Englisch
    Erscheinungsdatum 2019-11-04
    Erscheinungsland Canada
    Dokumenttyp Case Reports ; Journal Article
    ZDB-ID 215506-0
    ISSN 1488-2329 ; 0008-4409 ; 0820-3946
    ISSN (online) 1488-2329
    ISSN 0008-4409 ; 0820-3946
    DOI 10.1503/cmaj.190710
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel: Novel therapeutic agents for lowering low density lipoprotein cholesterol

    Joy, Tisha R

    Pharmacology and therapeutics. 2012 July, v. 135, no. 1

    2012  

    Abstract: Elevated low density lipoprotein cholesterol (LDL-C) levels have been associated with an increased risk for cardiovascular disease (CVD). Despite a 25–30% reduction in CVD risk with LDL-C reducing strategies, there is still a significant residual risk. ... ...

    Abstract Elevated low density lipoprotein cholesterol (LDL-C) levels have been associated with an increased risk for cardiovascular disease (CVD). Despite a 25–30% reduction in CVD risk with LDL-C reducing strategies, there is still a significant residual risk. Moreover, achieving target LDL-C values in individuals at high CVD risk is sometimes limited because of tolerability and/or efficacy. Thus, novel therapeutic agents are currently being developed to lower LDL-C levels further. This review will highlight some of these therapeutic agents including anti-sense oligonucleotides focused on apolipoprotein B, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, microsomal triglyceride transfer protein inhibitors, and thyromimetics. For each therapeutic class, an overview of the mechanism of action, pharmacokinetic data, and efficacy/safety evidence will be provided.
    Schlagwörter apolipoprotein B ; cardiovascular diseases ; low density lipoprotein cholesterol ; mechanism of action ; oligonucleotides ; pharmacokinetics ; risk ; subtilisin ; triacylglycerols
    Sprache Englisch
    Erscheinungsverlauf 2012-07
    Umfang p. 31-43.
    Erscheinungsort Elsevier Inc.
    Dokumenttyp Artikel
    ZDB-ID 194735-7
    ISSN 1879-016X ; 0163-7258
    ISSN (online) 1879-016X
    ISSN 0163-7258
    DOI 10.1016/j.pharmthera.2012.03.005
    Datenquelle NAL Katalog (AGRICOLA)

    Zusatzmaterialien

    Kategorien

  8. Artikel: Novel HDL-based therapeutic agents

    Joy, Tisha R

    Pharmacology and therapeutics. 2012 July, v. 135, no. 1

    2012  

    Abstract: Reduction in low-density lipoprotein cholesterol (LDL-C) levels has been associated with a 25–30% reduction in cardiovascular disease risk. However, there still remains a significant and quantifiable risk. Since epidemiologic data have demonstrated that ... ...

    Abstract Reduction in low-density lipoprotein cholesterol (LDL-C) levels has been associated with a 25–30% reduction in cardiovascular disease risk. However, there still remains a significant and quantifiable risk. Since epidemiologic data have demonstrated that low levels of high-density lipoprotein cholesterol (HDL-C) are associated with an increased risk for cardiovascular disease, novel therapeutic agents are currently being developed to either raise HDL-C levels or enhance HDL functionality. This review will highlight some of these therapeutic agents including cholesteryl ester transfer protein inhibitors, apolipoprotein A-I mimetics, RVX-208, and apolipoprotein A-I based infusion therapies. For each therapeutic class, an overview of the mechanism of action, pharmacokinetic data, and efficacy/safety evidence will be provided.
    Schlagwörter apolipoprotein A-I ; cardiovascular diseases ; cholesteryl ester transfer protein ; high density lipoprotein cholesterol ; low density lipoprotein cholesterol ; mechanism of action ; pharmacokinetics ; risk
    Sprache Englisch
    Erscheinungsverlauf 2012-07
    Umfang p. 18-30.
    Erscheinungsort Elsevier Inc.
    Dokumenttyp Artikel
    ZDB-ID 194735-7
    ISSN 1879-016X ; 0163-7258
    ISSN (online) 1879-016X
    ISSN 0163-7258
    DOI 10.1016/j.pharmthera.2012.03.004
    Datenquelle NAL Katalog (AGRICOLA)

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Epistemological and ethical assessment of obesity bias in industrialized countries

    Azétsop Jacquineau / Joy Tisha R

    Philosophy, Ethics, and Humanities in Medicine, Vol 6, Iss 1, p

    2011  Band 16

    Abstract: Abstract Bernard Lonergan's cognitive theory challenges us to raise questions about both the cognitive process through which obesity is perceived as a behaviour change issue and the objectivity of such a moral judgment. Lonergan's theory provides the ... ...

    Abstract Abstract Bernard Lonergan's cognitive theory challenges us to raise questions about both the cognitive process through which obesity is perceived as a behaviour change issue and the objectivity of such a moral judgment. Lonergan's theory provides the theoretical tools to affirm that anti-fat discrimination, in the United States of America and in many industrialized countries, is the result of both a group bias that resists insights into the good of other groups and a general bias of anti-intellectualism that tends to set common sense against insights that require any thorough scientific analyses. While general bias diverts the public's attention away from the true aetiology of obesity, group bias sustains an anti-fat culture that subtly legitimates discriminatory practices and policies against obese people. Although anti-discrimination laws may seem to be a reasonable way of protecting obese and overweight individuals from discrimination, obesity bias can be best addressed by reframing the obesity debate from an environmental perspective from which tools and strategies to address both the social and individual determinants of obesity can be developed. Attention should not be concentrated on individuals' behaviour as it is related to lifestyle choices, without giving due consideration to the all-encompassing constraining factors which challenge the social and rational blindness of obesity bias.
    Schlagwörter Medical philosophy. Medical ethics ; R723-726 ; Medicine (General) ; R5-920 ; Medicine ; R ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Thema/Rubrik (Code) 170
    Sprache Englisch
    Erscheinungsdatum 2011-12-01T00:00:00Z
    Verlag BioMed Central
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Access to nutritious food, socioeconomic individualism and public health ethics in the USA: a common good approach.

    Azétsop, Jacquineau / Joy, Tisha R

    Philosophy, ethics, and humanities in medicine : PEHM

    2013  Band 8, Seite(n) 16

    Abstract: Good nutrition plays an important role in the optimal growth, development, health and well-being of individuals in all stages of life. Healthy eating can reduce the risk of chronic diseases, such as heart disease, stroke, diabetes and some types of ... ...

    Abstract Good nutrition plays an important role in the optimal growth, development, health and well-being of individuals in all stages of life. Healthy eating can reduce the risk of chronic diseases, such as heart disease, stroke, diabetes and some types of cancer. However, the capitalist mindset that shapes the food environment has led to the commoditization of food. Food is not just a marketable commodity like any other commodity. Food is different from other commodities on the market in that it is explicitly and intrinsically linked to our human existence. While possessing another commodity allows for social benefits, food ensures survival. Millions of people in United States of America are either malnourished or food insecure. The purpose of this paper is to present a critique of the current food system using four meanings of the common good--as a framework, rhetorical device, ethical concept and practical tool for social justice. The first section of this paper provides a general overview of the notion of the common good. The second section outlines how each of the four meanings of the common good helps us understand public practices, social policies and market values that shape the distal causal factors of nutritious food inaccessibility. We then outline policy and empowerment initiatives for nutritious food access.
    Mesh-Begriff(e) Food Supply ; Humans ; Nutritive Value ; Policy Making ; Public Health/ethics ; Social Class ; Social Justice ; United States
    Sprache Englisch
    Erscheinungsdatum 2013-10-29
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 2229777-7
    ISSN 1747-5341 ; 1747-5341
    ISSN (online) 1747-5341
    ISSN 1747-5341
    DOI 10.1186/1747-5341-8-16
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang